Absci
Absci is a Vancouver, Washington-based generative AI drug creation company (NASDAQ: ABSI) using AI and synthetic biology to design de novo antibodies in silico against specified epitopes. Its Integrated Drug Creation platform couples generative AI models — including the Origin-1 antibody foundation model — with a 77,000+ sq ft wet lab running proprietary SoluPro and ACE Assay technologies, screening millions of antibody sequence variants per cycle. The data flywheel between in silico design and high-throughput wet lab validation completes in as little as six weeks and can advance from target identification to development candidate in roughly 14 months. Absci's internal pipeline includes ABS-101, an anti-TL1A antibody for inflammatory bowel disease now in Phase 1; ABS-201, a novel anti-PRLR antibody for androgenetic alopecia in the Phase 1/2a HEADLINE trial; and ABS-301, a first-in-class AI-discovered oncology antibody. Strategic partnerships span AstraZeneca, Merck, Almirall, Twist Bioscience, NVIDIA, Owkin, Caltech, and the Gates Foundation. Absci's commercial model is therapeutic development (internal pipeline plus partnered programs and royalties); there is no public developer API, SDK, or open-source release of the Origin-1 model or its drug creation platform.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles Absci the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Absci scores 6.8/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Absci
Each block below is one kind of artifact we hold for Absci. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for Absci — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Access & Security 1
Authentication, authorization, and security posture
Learn 1
Tutorials, courses, talks, and written guidance
Operate 2
Status, limits, changes, and where to get help
Company 7
The organization behind the API
Scroll within the panel for all 7 ·
Other 4
Properties that don't map to a standard resource type
← All providers · Data indexed from github.com/api-evangelist/absci · machine-readable index on apis.io